Antimicrobial Susceptibility Testing Patterns of

antimicrobial resistance extensively drug resistant N. gonorrhoeae high level resistance multidrug resistant N. gonorrhoeae penicillinase producing-neisseria gonorrhoeae quinolone-resistant N. gonorrhoeae

Journal

Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042

Informations de publication

Date de publication:
02 Jun 2022
Historique:
received: 14 04 2022
revised: 25 05 2022
accepted: 28 05 2022
entrez: 23 6 2022
pubmed: 24 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

Antimicrobial resistance (AMR) is global health threat that is on the increase, and it has been adversely affecting the proper management of sexually transmitted infections (STI). Data on antimicrobial susceptibility testing patterns of N. gonorrhoeae are limited in local settings. We determined in vitro antimicrobial susceptibility and phenotypic profiles of N. gonorrhoeae isolated from STI/Outpatient Department (OPD) clinics. Minimum Inhibitory Concentrations (MIC) (µg/mL) were determined using E-Test and agar dilution methods for previously and currently recommended antimicrobial agents. A total of 164 N. gonorrhoeae isolates from urethral discharge and endocervical swabs were tested. The prevalence of resistant N. gonorrhoeae to tetracycline, norfloxacin, penicillin and ciprofloxacin were 98.6%, 82.2%, 84.3% and 75.6%, respectively. None of the isolates was resistant to kanamycin. Penicillinase producing N. gonorrhoeae (PPNG) was found to be 73.7%, with 56.7% and 43.3% observed among isolates from women and men, respectively. Tetracycline resistant-N. gonorrhoeae (TRNG) was found to be 34.0%, and QRNG with HLR to ciprofloxacin was 79.9%. The overall MDR-NG was 79.9%, and XDR-NG was 3.6%. MIC50 and MIC90 were 4.0 and 8.0 and 2.0 and 4.0 µg/mL for ciprofloxacin and norfloxacin, respectively. Dendrograms showed that 44 phenotypic groups are associated with a high rate of AMR among high MDR-NG and moderate XDR-NG isolates. The predominant groups of quinolone-resistant N. gonorrhoeae (QRNG)+PPNG (34.7%) and QRNG+PPNG+TRNG (32.9%) were observed among the isolates having HLR to ciprofloxacin. We reported a high prevalence of AMR (>90%) to previously recommended antimicrobials used for the treatment of gonorrhoea. Multidrug resistant N. gonorrhoeae (MDR-NG) was highly reported, and extensively drug resistant (XDR-NG) has gradually increased to the currently recommended cephalosporins including ceftriaxone and cefixime. Heterogeneous groups of QRNG+PPNG+ and QRNG+PPNG+TRNG were highly resistant to penicillin, tetracycline, ciprofloxacin and norfloxacin. A surveillance program is imperative in the country to curb the spread of AMR.

Identifiants

pubmed: 35736968
pii: tropicalmed7060089
doi: 10.3390/tropicalmed7060089
pmc: PMC9231259
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Emerg Infect Dis. 2017 May;23(5):830-832
pubmed: 28418303
Sex Transm Dis. 2001 Sep;28(9):539-45
pubmed: 11518873
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Sex Transm Dis. 1997 Jan;24(1):32-7
pubmed: 9018781
Sex Transm Dis. 1988 Oct-Dec;15(4):217-24
pubmed: 3147526
Sex Transm Infect. 1999 Apr;75(2):107-11
pubmed: 10448363
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
Genitourin Med. 1995 Feb;71(1):9-12
pubmed: 7750963
J Clin Microbiol. 2000 Oct;38(10):3825-6
pubmed: 11015410
Antimicrob Agents Chemother. 2011 Aug;55(8):3882-8
pubmed: 21606224
J Antimicrob Chemother. 2012 Aug;67(8):1858-60
pubmed: 22566592
BMC Infect Dis. 2015 Jan 31;15:29
pubmed: 25637258
Sex Transm Dis. 1997 Jul;24(6):378-85
pubmed: 9243747
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
Tuberculosis (Edinb). 2015 Mar;95(2):137-41
pubmed: 25522842
Sex Transm Infect. 2008 Oct;84(5):352-5
pubmed: 18596070
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7518-7521
pubmed: 27736753
Ann N Y Acad Sci. 2011 Aug;1230:E19-28
pubmed: 22239555
Emerg Infect Dis. 2012 Aug;18(8):1290-7
pubmed: 22840274
PLoS Pathog. 2016 May 19;12(5):e1005611
pubmed: 27196299
Sex Transm Dis. 2011 Nov;38(11):1056-8
pubmed: 21992984
Antimicrob Agents Chemother. 1986 Nov;30(5):664-70
pubmed: 3099640
Lancet. 2005 Oct 1;366(9492):1159
pubmed: 16198757
BMC Infect Dis. 2015 Aug 21;15:364
pubmed: 26293005
EMBO J. 1999 Jan 15;18(2):339-52
pubmed: 9889191
Curr Opin Infect Dis. 2009 Feb;22(1):87-91
pubmed: 19532086
BMC Infect Dis. 2014 Jun 19;14:342
pubmed: 24947981
BMC Infect Dis. 2014 Nov 27;14:622
pubmed: 25427572
Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45
pubmed: 21576437
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80
pubmed: 22155830
Braz J Microbiol. 2017 Oct - Dec;48(4):617-628
pubmed: 28754299
Lancet. 1977 Jun 4;1(8023):1205
pubmed: 68298
S Afr Med J. 1977 Apr 23;51(17):568
pubmed: 405745

Auteurs

Said Aboud (S)

Departments of Microbiology and Immunology, Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam P.O. Box 65001, Tanzania.

Simon N Buhalata (SN)

Departments of Microbiology and Immunology, Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam P.O. Box 65001, Tanzania.
National Institute for Medical Research, Mwanza Research Centre, Mwanza P.O. Box 1462, Tanzania.

Onduru G Onduru (OG)

Department of Pathology, College of Medicine, Kamuzu University of Health Sciences, Blantyre P.O. Box 360, Malawi.

Mercy G Chiduo (MG)

National Institute for Medical Research, Tanga Research Centre, Tanga P.O. Box 5004, Tanzania.

Gideon P Kwesigabo (GP)

Departments of Microbiology and Immunology, Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam P.O. Box 65001, Tanzania.

Stephen E Mshana (SE)

Department of Medical Microbiology, Catholic University of Health and Allied Sciences (CUHAS), Mwanza P.O. Box 1370, Tanzania.

Alphaxard M Manjurano (AM)

National Institute for Medical Research, Mwanza Research Centre, Mwanza P.O. Box 1462, Tanzania.

Mansuet M Temu (MM)

National Institute for Medical Research, Mwanza Research Centre, Mwanza P.O. Box 1462, Tanzania.

Coleman Kishamawe (C)

National Institute for Medical Research, Mwanza Research Centre, Mwanza P.O. Box 1462, Tanzania.

John M Changalucha (JM)

National Institute for Medical Research, Mwanza Research Centre, Mwanza P.O. Box 1462, Tanzania.

Classifications MeSH